LHDX - Lucira Health files with FDA for emergency use of at-home COVID-19 flu test

Lucira Health (NASDAQ:LHDX) said it submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) of its COVID-19 & Flu test. The company said the request is for prescription at-home use of the PCR-quality test for COVID-19 or Influenza. Lucira is seeking FDA authorization before the upcoming fall and winter season. The company noted that its standalone COVID-19 test was the first at-home COVID-19 test to receive an EUA from the FDA in November 2020. The Lucira COVID-19 & Flu test uses the same platform and palm-sized device design and independently tests for COVID-19, Flu A, and Flu B from a single nasal swab, producing results within 30 minutes.

For further details see:

Lucira Health files with FDA for emergency use of at-home COVID-19, flu test